Q-linea announced that clinical insights from two prospective studies will be presented at the AMCLI congress. Data will be shared both from the largest comparative study performed in Europe so far between rapid AST systems and from the ongoing health economics research (HEOR) study Lifetimes. At the upcoming conference, AMCLI (Associazione Microbiologi Clinici Italiani) National Congress in Rimini, Italy on March 9, 2024, Q-linea will host a workshop titled "ASTar in action: Rapid MIC in the management of the patients with bloodstream infection".

The workshop will showcase clinical insights from two prospective studies. Prof. Alexia Verroken, from Cliniques Universitaires Saint-Luc, Brussels, will present the results of a trial investigating the clinical impact of rapid AST on positive blood cultures from 200 patients with bacteremia. The study is a comparative analysis of Q-linea's ASTar system with two other rapid AST technologies, providing insights into user-friendliness, performance, and clinical impact of each approach.

Prof. Maurizio Sanguinetti, from Universita Cattolica del Sacro Cuore, Rome, will present interim data from the ongoing Lifetimes health economics study, including 160 prospective ICU patients with bloodstream infections.